FDA Issues Final Guidance for Model-Informed Drug Development

The U.S. Food and Drug Administration has published its final guidance on Model-Informed Drug Development (MIDD) principles. This document, developed in collaboration with the International Council for Harmonisation, offers recommendations for the planning, evaluation, and documentation of MIDD evidence. The initiative seeks to establish a consistent assessment framework and simplify regulatory processes for pharmaceutical companies.